'For patients in a late-stage trial, the drug called donanemab slowed progression of the disease by 35 per cent compared with those who took the placebo during an 18-month treatment period. The decline in patients’ ability to perform daily tasks was 40 per cent lower for those on the drug.

However, the drug displayed severe side effects such as brain swelling and bleeding and three people on the trial died.'
#alzheimers #alzheimersdisease

https://www.ft.com/content/11a59576-e057-433a-b1f9-393159bda85c